Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Shire Income Up In 2nd-Quarter Ahead Of Takeover By Takeda

Tue, 31st Jul 2018 12:51

LONDON (Alliance News) - Irish biotechnology company Shire PLC on Tuesday posted a more than doubled pretax income in the second quarter, ahead of its upcoming takeover by Takeda Pharmaceutical Co Ltd.

In the three months to June 30, Shire recorded pretax income from continuing operations, excluding equity earnings, of USD734.2 million. This compares with a USD261.5 million income for the same quarter in 2017.

The company's revenue for the period was USD3.92 billion, up from USD3.75 billion the year before. Product sales made up the bulk of this, increasing 6% to USD3.81 billion from USD3.59 billion.

Immunology led product sales growth, climbing 13%, alongside a 61% rise in internal medicine sales and a 75% growth in Ophthalmics sales.

Royalties and other revenue dropped 28% to USD111 million from USD154 million due to lower royalties from thyroid drug Sensipar.

Revenue from ADHD drug Adderall XR was reclassified to product sales from royalty revenue, alongside other changes under the new accounting standard.

The company said that it will pay a dividend per share of 5.60 US cents for the interim, up 10% from 5.09 cents in 2017.

Shire intends to sell its oncology franchise to Servier SAS in the upcoming third quarter of 2018. At present, Shire's guidance 2018 is unchanged but it will be updated once the franchise is sold. The company said its 2020 guidance is likewise unchanged but has yet to be updated to include the sale of oncology.

"During the quarter, our board reached an agreement with the Takeda board on the terms of a recommended offer for Takeda to acquire Shire. The acquisition is expected to close in the first half of 2019, subject to shareholder approval of both companies and additional regulatory approvals. In the meantime, we remain resolutely focused on execution as these results demonstrate," said Shire Chief Executive Flemming Ornskov.

Shire agreed a takeover by Takeda in early May and gained unconditional clearance from the US Federal Trade Commission at the start of this month. The deal values Shire at GBP46.00 billion.

Shares in Shire were up 0.5% at 4,335.00 pence on Tuesday.

More News
8 May 2018 11:03

WORLD NEWS SCHEDULE AT 1000 GMT/6 AM ET

Editor: Angus MacSwan + 44 207 542 7923 Picture Desk: Singapore + 65 6870 3775 Graphics queries: + 65 6870 3595 (All times GMT) TOP STORIES Trump to reveal Iran

Read more
8 May 2018 09:30

Reuters Business News Schedule at 0830 GMT/430AM ET

Editor: Keith Weir, +44 20 7542 8022 Global Picture Desk: +65 6870 3775 Global Graphics Desk: + 65 6870 3595 (All times GMT / ET) Receive this schedule by Takeda $62 to

Read more
8 May 2018 08:06

Nikkei rises as banks rally; Takeda up ahead of acquisition news

By Ayai Tomisawa TOKYO, May 8 (Reuters) - Japan's Nikkei share average rose on Tuesday as banking stocks rallied while Takeda Pharmaceutical climbed ahead of news the drugmaker had to 4

Read more
8 May 2018 07:59

TOP NEWS: Shire Agrees GBP46 Billion Takeover Deal With Takeda

LONDON (Alliance News) - Irish pharmaceutical company Shire PLC on Tuesday said it has agreed a takeover deal with Japanese peer Takeda Pharmaceutical Co.Takeda is to pay USD30.33 in cash a

Read more
8 May 2018 07:47

LONDON MARKET PRE-OPEN: Lower Call; Shire Agrees Takeda Deal

LONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday ahead of US President Donald Trump's decision on whether to scrap the nuclear deal with Iran, while in London

Read more
8 May 2018 07:44

UPDATE 1-Japan's Takeda agrees $62 billion takeover of Shire

LONDON, May 8 (Reuters) - Takeda Pharma agreed to buy London-listed Shire for 45.3 billion pounds ($61.50 billion) on Tuesday after the Japanese company raised the amount of cash in its offer to a

Read more
8 May 2018 07:18

Japan's Takeda agrees $62 billion takeover of Shire

LONDON, May 8 (Reuters) - Takeda Pharma agreed to buy London-listed Shire for 46 billion pounds ($62.42 billion) on Tuesday after the Japenese company raised the amount of cash in its offer to to

Read more
8 May 2018 06:25

UK Stocks-Factors to watch on May 8

May 8 (Reuters) - Britain's FTSE 100 index is seen opening 13 points higher at 7,580 on Tuesday, according to financial bookmakers. * VIRGIN MONEY: Virgin Money said on Monday it had received an

Read more
8 May 2018 03:31

Nikkei rises, helped by tech stocks, banks, Takeda's Shire offer

By Ayai Tomisawa TOKYO, May 8 (Reuters) - Japan's Nikkei share average rose on Tuesday as tech shares rallied and Takeda Pharmaceutical jumped after a report the drugmaker will make a 2

Read more
3 May 2018 14:49

Vodafone closes in on game-changing Liberty Global deal

By Ben Martin and Paul Sandle LONDON, May 3 (Reuters) - Vodafone is nearing a transformational deal to buy continental European assets from cable giant Liberty Global and could announce an

Read more
30 Apr 2018 05:05

FOREX-Dollar below 3-month highs as U.S. 10-year yield pulls back

* Dollar index down from Friday's 3-1/2 month peak * Pullback in U.S. 10-year yield dents dollar's momentum * Dollar/yen on track for biggest monthly gain since 2016 *

Read more
27 Apr 2018 05:24

FOREX-Dollar at 3-1/2-month high on elevated yields, euro soft after ECB

* Dollar helped by higher yields; lack of trade, geopolitical news * Euro loses steam after Draghi sounds cautious on economy * Yen capped, sterling helped by Takeda's bid to buy

Read more
27 Apr 2018 02:04

FOREX-Dollar at 3-1/2-month high on elevated yields, euro soft after ECB

* Dollar helped by higher yields; lack of trade, geopolitical news * Euro loses steam after Draghi sounds cautious on economy * Yen capped, sterling helped by Takeda's bid to buy

Read more
26 Apr 2018 16:17

EXTRA: Bid-Target Shire's Stellar First-Quarter Performance Overlooked

LONDON (Alliance News) - Shire PLC delivered a strong first-quarter performance, but the report was overshadowed by the protracted takeover approach by Japan's Takeda Pharmaceutical Co, to the

Read more
26 Apr 2018 12:45

UPDATE 1-Bid target Shire grows earnings 6 pct, holds cautious outlook

LONDON, April 26 (Reuters) - Shire, the London-listed drugmaker targeted by Takeda Pharmaceutical , reported a 6 percent rise in first-quarter earnings on Thursday, while keeping its cautious for

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.